<DOC>
	<DOCNO>NCT00298181</DOCNO>
	<brief_summary>Selectins implicate pathogenesis ischemia/reperfusion ( I/R ) -induced kidney injury resultant DGF . PSGL-1 ligand P- , E- , L-selectin . It report YSPSL ( rPSGL-Ig ) block P-selectin , less degree , E- L-selectin . Both sPSGL-1 YSPSL ( rPSGL-Ig ) show animal model reduce cytokine tissue damage associate ischemia reperfusion improve renal function post-transplant . Therefore , current phase I/II clinical study design ass safety efficacy YSPSL ( rPSGL-Ig ) prevent DGF patient undergo cadaveric kidney transplant determine dose future pivotal study .</brief_summary>
	<brief_title>YSPSL Prevention Delayed Graft Function Part A</brief_title>
	<detailed_description>This multicenter , single-dose , dose-escalation study . The study 2 part : first , Part A , open label evaluation single dose four dose cohort second , Part B randomize , double-blind , placebo-controlled , single-dose , dose-escalation study two dose cohort . Patients undergo cadaveric kidney transplantation risk development DGF , base upon know risk factor , eligible participate study . A maximum 24 patient enrolled Part A study . 60 patient enrolled Part B .</detailed_description>
	<mesh_term>Delayed Graft Function</mesh_term>
	<criteria>primary cadaver renal transplant Other inclusion criterion delineate protocol Full criterion delineate protocol Patient plan transplant donor kidney nonheartbeating donor ; Patient plan transplant kidney implant en bloc ( dual kidney transplant ) donor &lt; 6 year age ; Patient plan transplant kidney donor receive investigational therapy design reduce impact ischemia/reperfusion ( I/R ) injury , DGF , donorrelated immune event ; Patient plan receive living donor kidney ; Patient plan receive ABOincompatible donor kidney .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>